atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, has announced that the company has entered into a term loan facility for up to $175 million with Hercules Capital, Inc. (NYSE: HTGC).
Latham & Watkins LLP represents atai in the transaction with a team led by New York corporate partner Nathan Ajiashvili and Bay Area finance partner Dan Van Fleet, with finance associates Hyunji Lee and Jude Baldo.
